-
公开(公告)号：US09867803B2
公开(公告)日：2018-01-16
申请号：US15600473
申请日：2017-05-19
Inventor： Qingping Zeng , Andras Toro , John Bruce Patterson , Warren Stanfield Wade , Zoltan Zubovics , Yun Yang , Zhipeng Wu
IPC: A61K31/352 , C07D311/16 , C07D405/10 , C07D417/04 , A61K31/366 , C07D409/04 , C07D405/04 , C07D401/04 , C07D311/94 , C07D311/20 , C07D401/12 , C07D311/22 , C07D311/12 , C07D217/08 , C07D217/02 , A61K45/06 , A61K31/5377 , A61K31/496 , A61K31/4545 , A61K31/454 , A61K31/453 , A61K31/452 , A61K31/4439 , A61K31/4433 , A61K31/427 , A61K31/423 , A61K31/4184 , A61K31/4172 , A61K31/4155 , A61K31/415 , A61K31/4045 , A61K31/404 , A61K31/4025 , A61K31/381 , A61K31/37 , A61K31/343
CPC classification number: A61K31/366 , A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439 , A61K31/452 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D217/02 , C07D217/08 , C07D311/12 , C07D311/16 , C07D311/20 , C07D311/22 , C07D311/94 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D417/04 , Y02A50/389 , Y02A50/393
Abstract: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
-
公开(公告)号：US09856266B2
公开(公告)日：2018-01-02
申请号：US15349872
申请日：2016-11-11
Inventor： Qingping Zeng , Warren S. Wade , John Bruce Patterson
IPC: C07D295/192 , C07D413/06 , C07D417/06 , C07D417/04 , C07D403/04 , C07D405/06 , C07D295/112 , C07D277/56 , C07D417/12 , C07D239/38 , C07D249/06 , C07D207/16 , C07D307/68 , C07D239/26 , C07D487/08 , C07D207/14 , C07D207/08 , C07D213/74 , C07D295/108 , C07D401/12 , C07D213/38 , C07D211/26 , C07D211/58 , C07D401/04 , C07D295/26 , C07D295/32 , C07D277/12 , C07D263/34 , C07D409/12 , C07D333/38 , C07D277/18
CPC classification number: C07D487/08 , C07C59/74 , C07C65/30 , C07C69/738 , C07C235/78 , C07C235/84 , C07D207/08 , C07D207/14 , C07D207/16 , C07D211/26 , C07D211/58 , C07D211/62 , C07D211/66 , C07D211/98 , C07D213/36 , C07D213/38 , C07D213/74 , C07D213/81 , C07D213/82 , C07D239/26 , C07D239/38 , C07D249/06 , C07D263/34 , C07D277/12 , C07D277/18 , C07D277/42 , C07D277/56 , C07D295/108 , C07D295/112 , C07D295/185 , C07D295/192 , C07D295/26 , C07D295/32 , C07D307/68 , C07D333/38 , C07D333/40 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/12
Abstract: The invention provides compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
-
公开(公告)号：US20170326104A1
公开(公告)日：2017-11-16
申请号：US15600473
申请日：2017-05-19
Inventor： Qingping Zeng, Jr. , Andras Toro , John Bruce Patterson , Warren Stanfield Wade , Zoltan Zubovics , Yun Yang , Zhipeng Wu
IPC: A61K31/366 , A61K31/343 , C07D405/10 , C07D405/04 , C07D401/12 , C07D401/04 , C07D311/94 , C07D311/22 , C07D311/20 , C07D311/16 , C07D311/12 , C07D217/08 , C07D217/02 , A61K45/06 , A61K31/5377 , A61K31/496 , A61K31/4545 , A61K31/454 , A61K31/453 , A61K31/452 , A61K31/4439 , A61K31/4433 , A61K31/427 , A61K31/423 , A61K31/4184 , A61K31/4172 , A61K31/4155 , A61K31/415 , A61K31/4045 , A61K31/404 , A61K31/4025 , A61K31/381 , A61K31/37 , A61K31/352 , C07D409/04 , C07D417/04
CPC classification number: A61K31/366 , A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439 , A61K31/452 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D217/02 , C07D217/08 , C07D311/12 , C07D311/16 , C07D311/20 , C07D311/22 , C07D311/94 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D417/04 , Y02A50/389 , Y02A50/393
Abstract: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
